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Abstract
Glutaric aciduria type 1 (GA1) is a rare neurometabolic disorder, caused by
inherited deficiency of glutaryl-CoA dehydrogenase, mostly affecting the brain.
Early identification by newborn screening (NBS) significantly improves neurologic
outcome. It has remained unclear whether recommended therapy, particular low
lysine diet, is safe or negatively affects anthropometric long-term outcome. This
national prospective, observational, multi-centre study included 79 patients identi-
fied by NBS and investigated effects of interventional and non-interventional
parameters on body weight, body length, body mass index (BMI) and head cir-
cumference as well as neurological parameters. Adherence to recommended
maintenance and emergency treatment (ET) had a positive impact on neurologic
outcome and allowed normal anthropometric development until adulthood. In
contrast, non-adherence to ET, resulting in increased risk of dystonia, had a nega-
tive impact on body weight (mean SDS −1.07; P = .023) and body length (mean
SDS −1.34; P = −.016). Consistently, longitudinal analysis showed a negative
influence of severe dystonia on weight and length development over time
(P < .001). Macrocephaly was more often found in female (mean SDS 0.56) than
in male patients (mean SDS −0.20; P = .049), and also in individuals with high
excreter phenotype (mean SDS 0.44) compared to low excreter patients (mean
SDS −0.68; P = .016). In GA1, recommended long-term treatment is effective and
allows for normal anthropometric long-term development up to adolescence, with
gender- and excreter type-specific variations. Delayed ET and severe movement
disorder result in poor anthropometric outcome.
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1 | INTRODUCTION
Glutaric aciduria type 1 (GA1; OMIM #231670) is a
rare inherited neurometabolic disorder of L-lysine,
L-hydroxylysine and L-tryptophan metabolism. It is cau-
sed by inborn deficiency of glutaryl-CoA dehydrogenase
(GCDH; EC 1.3.8.6) resulting in accumulation of
glutaryl-CoA and, subsequently, glutarylcarnitine
(C5DC), glutaric acid (GA) and 3-hydroxyglutaric acid
(3OHGA).
During the first months of life, untreated patients are
usually asymptomatic or show transiently delayed motor
development or muscular hypotonia.1,2 Between
3-36 months of age, however, the majority of untreated
individuals develops a complex dystonic movement disor-
der (MD) due to striatal injury precipitated by acute
encephalopathic crises (EC) during febrile illness or other
causes of catabolic state (acute onset), but in a relevant
number of individuals MD manifests without apparent
preceding crises (insidious onset). Two biochemical
groups were distinguished based on the GA concentra-
tion in urine3: a high excreter (HE) phenotype in individ-
uals with urinary GA concentrations ≥100 mmol/mol
creatinine and a low excreter (LE) phenotype if the GA
concentration is below this cut-off. Urinary 3OHGA is
elevated in most patients and may be the only biochemi-
cal derangement of LE individuals, with much less varia-
tion than GA. Urinary GA excretion inversely correlates
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with the GCDH residual enzyme activity, with HE indi-
viduals showing 0% to 2% and LE patients 3% to 30% of
residual GCDH activity.4 Both subtypes are thought to
share the same risk for striatal injury during infancy. This
is explained by intracerebral and intramitochondrial
entrapment of neurotoxic dicarboxylic metabolites sec-
ondary to the lack of specific transporters for CoA esters
(inner mitochondrial membrane) and dicarboxylic acids
(blood-brain barrier), resulting in accumulation of these
metabolites in vulnerable compartments5,6 and bioener-
getic impairment.7,8 However, recent 1H-MRS studies
revealed higher intracerebral in vivo concentrations of
neurotoxic metabolites and a higher frequency of mag-
netic resonance imaging (MRI) abnormalities in HE
patients compared to LE patients.1,4,9 The underlying
mechanism remains to be elucidated; glutarylation of
mitochondrial proteins, such as glutamate dehydroge-
nase, in astroglial cells might be involved.10,11
Implementation of GA1 into national newborn screen-
ing (NBS) programmes has significantly improved neuro-
logic outcome, particularly in individuals following
recommended therapy.12-18 Evidence-based treatment
guidelines, established and twice revised by an international
guideline committee,19-21 recommend low lysine diet, sup-
plemented with lysine-free, tryptophan-reduced, arginine-
fortified amino acid mixtures up to age 6 years and a
relaxed protein-controlled diet for older patients, and addi-
tional lifelong oral carnitine supplementation for mainte-
nance treatment (MT). Rapid start of emergency treatment
(ET) in every potentially threatening episode that may pre-
cipitate catabolism is recommended in patients up to
6 years while efficacy in older patients is unclear.
Safety and anthropometric outcome of recommended
dietary long-term treatment has not yet been prospec-
tively studied in screened and early treated GA1 patients
beyond the age of 6 years.22 Therefore, the aim of this
study is to investigate the long-term anthropometric and
neurologic development of patients with GA1 up to ado-
lescence and to evaluate the impact of interventional and
non-interventional parameters on body weight, body
length, body mass index (BMI) and head circumference
as well as on neurologic outcome.
2 | METHODS
2.1 | Study population
This national multi-centre study is a prospective, non-
randomised, non-controlled observational trial for
patients with GA1. Inclusion criteria were (a) identifica-
tion by NBS between 1 January 1999 and 1 July 2016 in
Germany; (b) confirmation of diagnosis by quantitative
analysis of urinary GA and 3OHGA and/or GCDH gene
analysis and/or quantitative residual enzyme activity of
GCDH; and (c) written informed consent from patients
and/or parents. Patients who did not fulfil these criteria
were excluded. All patients were included in a patient
registry established and managed by the European regis-
try and network for Intoxication type Metabolic Diseases
(E-IMD; https://www.eimd-registry.org/).23,24
2.2 | Outcome variables
Anthropometric data, specifically body weight, body
length, BMI and head circumference, and all therapeutic
follow-up parameters were assessed prospectively. All
anthropometric measurements were transformed into a
SD score (SDS) using the LMS method and age-
dependent standard values to assess and compare anthro-
pometric development in different age groups.25,26
2.3 | Biochemical subtype
Biochemical subtypes were defined as previously
described.3 Urinary GA was <100 mmol/mol creatinine
or even normal in LE patients and ≥100 mmol/mol creat-
inine in HE patients.
2.4 | Treatment and supervision by a
specialised metabolic centre
Guidelines recommend the use of MT and ET, and
supervision by a specialised metabolic centre.21 MT con-
sists of (a) age-adapted low lysine diet with supplemen-
tation of a lysine-free, tryptophan-reduced and arginine-
fortified amino acid supplement until the age of 6 years;
(b) protein-controlled diet avoiding products with high
lysine content and excessive protein intake for patients
older than 6 years; and (c) lifelong oral carnitine supple-
mentation. ET consists of (a) high carbohydrate supply;
(b) low to no protein intake; and (c) increased carnitine
dose. ET should be started without any delay, that is,
within 24 hours after the onset of alarming symptoms,
and in every potentially catabolic situation such as
febrile illness and surgery. Adherence to ET and MT
was considered (AMT, AET) if all criteria listed above
were fulfilled during the study interval. Supervision by a
metabolic centre starting during the neonatal period
and lasting until adulthood was prerequisite for being
classified alike.
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2.5 | Migration background
Migration background was defined by at least one parent
being born neither in Germany nor a German-speaking
(part of a) country such as Austria or Switzerland.
2.6 | Neurologic manifestations
Neurologic manifestations were classified depending on
the presence and severity of a dystonic MD. Patients were
classified as (a) asymptomatic in the absence of MD;
(b) mildly affected if MD did not cause significant disabil-
ity in daily life; (c) moderately affected if MD caused
motor disability affecting daily life, but with some motor
functions being preserved; and (d) severely affected if
MD caused significant disability with few motor skills
left.12 Onset of dystonic MD was (a) acute with EC; or
(b) insidious without an apparent crisis.
2.7 | Statistical analysis
Independent variables used for anthropometric outcome
analysis were (a) severity of a dystonic MD;
(b) biochemical subtype; (c) gender; (d) migration back-
ground; (e) adherence to MT; (f) adherence to ET; and
(g) supervision by a specialised metabolic centre. Ana-
lyses were computed with the statistical package R.27 In a
cross-sectional analysis, welch two sample t-test was
applied to evaluate effects of the aforementioned vari-
ables on anthropometric parameters. Variables with sig-
nificant effects (P < .1) were selected for a linear model
to assess interaction. A linear mixed model was used for
longitudinal analysis of anthropometric development.
2.8 | Ethics approval
The Institutional Ethics Committee of the coordinating
centre and all contributing study sites approved the study
(University Hospital Heidelberg, application number
S-525/2010).
3 | RESULTS
3.1 | Study sample and epidemiology
This study includes 79 patients (41 females, 38 males)
with confirmed diagnosis of GA1 following identification
by NBS. Detailed neurologic outcome was published sep-
arately.13 Due to incomplete data sets, eight patients
identified by NBS could not be included. The study popu-
lation comprised 92% (59/64) of all GA1 patients identi-
fied by NBS in Germany and reported by the German
National Society for Newborn Screening between January
2004 and July 2016. Median age at diagnosis was 7 days
(range 2-217 days, interquartile range [IQR] 6-10 days)
with a cumulative follow-up time of all patients of
663 years. Median age at last visit was 8.77 years (range
0.77-17.75 years, IQR 4.18-12.66 years) with 66 patients
(84%) being older than 3 years and 49 patients (62%)
older than 6 years at last visit. Seventy patients (89%)
were regularly followed by a specialised metabolic centre,
while nine patients (11%) were followed by local paedia-
tricians and children's hospitals without metabolic focus.
Fifty-nine patients (75%) had HE phenotype whereas
18 patients (23%) were classified as LE. For two geneti-
cally confirmed patients the biochemical phenotype was
not reported. Thirty-seven patients' parents (47%) were
born in Germany, and 42 patients (53%) had a migration
background. Up to age 6 years, adherence to MT recom-
mendations for calculated diet and carnitine supplemen-
tation was documented in 23/30 patients (77%), while
seven patients did not follow the recommendations
(23%). After the age of 6 years, MT was adequate in 39/49
patients (80%) with 29 patients (59%) following the rec-
ommendations for protein-controlled diet and 10 patients
(20%) continuing calculated diet whereas 10 patients
(20%) had no diet. In total, AMT was found in 62 patients
(78%; vs no AMT n = 17 [22%]). Reasons for non-adher-
ence to MT were non-compliance to the diet (n = 8),
feeding problems (n = 1), delayed start of MT (n = 2) or
inadequate dietary prescription (n = 6). Seventy patients
(89%) received AET before the age of 6 years, while it
was started with significant delay in nine patients (11%).
3.2 | Neurologic outcome
None of the patients showed irreversible neurologic
symptoms at time point of diagnosis, and at last visit, the
majority of patients (n = 53; 67%) still had not developed
motor symptoms. Twenty patients (25%) suffered from a
dystonic MD, n = 1 (1%) showed ataxia, while n = 5 (6%)
had minor neurologic abnormalities such as fine motor
deficits. Onset type of MD was acute following EC in nine
cases (45%) and insidious in 11 cases (55%). Dystonia was
mild in eight patients, moderate (n = 7) or severe (n = 5)
at last visit. During prospective follow-up, degree of MD
remained unchanged in 14 patients, whereas aggravation
was found in five patients (of which four had insidious
onset) and improvement in one. During the observational
period, none of the patients developed major or minor
motor symptoms after the age of 6 years. Impact of
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treatment quality on neurologic long-term outcome was
published previously.13
3.3 | Anthropometric outcome
Table 1 and Supporting Information Table S1 summa-
rise all anthropometric data collected at last visit, with
SDS indicating deviations from age group references.
In brief, body weight (mean SDS −0.09; SD 1.38), body
length (mean SDS −0.32; SD 1.29), BMI (mean SDS
0.13; SD 1.27) and head circumference (mean SDS 0.17;
SD 1.47) were within the reference range indicating
age-appropriate long-term development. In an addi-
tional longitudinal analysis, development of SDS was
analysed for weight (26 patients), length (25 patients),
BMI (25 patients) and head circumference (22 patients)
showing no age-dependent effects over time.
Next, we evaluated effects of interventional and non-
interventional variables on anthropometric long-term
development. Detailed data can be found in Supporting
Information Table S1.
3.4 | Effects of non-interventional
parameters
3.4.1 | Dystonic movement disorder
Asymptomatic patients and those with mild and moder-
ate MD showed normal development of weight up to
late adolescence (mean SDS −0.06, 0.53 and −0.26
respectively; Figure 1). In contrast, individuals with
severe dystonia had an impaired weight gain (mean
SDS −1.45; F[3,238] = 20.42; P < .001). Results for body
length were similar with asymptomatic and mildly
affected patients showing normal growth over time
(mean SDS 0.01 and 0.66 respectively). In contrast, lon-
gitudinal growth was impaired in individuals with mod-
erate and severe dystonia (mean SDS −0.76 and −0.94
respectively; F[3,238] = 7.55; P < .001; Supporting
Information Figure S1).
3.4.2 | Biochemical subtype
At last visit, patients with HE phenotype had a larger
head circumference (mean SDS 0.44) compared to
patients with LE phenotype (mean SDS −0.68;
P = .021, Figure 2). The effect was confirmed in a lin-
ear model (P = .016), but less pronounced in a longitu-
dinal analysis (mean SDS 0.73 and −0.58 respectively;
P = .089), however, including less patients (n = 22).
Exclusion of the two outliers (which, however, were
confirmed by multiple validation) from analysis had
an impact on the level of significance (mean SDS in LE
patients −0.17; P = .051 and P = .171 in the linear
model). Development of body weight, body length and,
subsequently, BMI did not differ between HE and LE
patients.
TABLE 1 Anthropometric data of the study population at last visit
Anthropometric parameter n Mean SDS SD Q1 Median Q3 Minimum Maximum
Body weight 79 -0.09 1.38 −0.66 0.09 0.65 −5.19 3.11
Body length 79 −0.32 1.29 −0.93 −0.28 0.53 −5.74 2.31
BMI 79 0.13 1.27 −0.64 0.21 0.82 −2.89 3.08
Head circumference 51 0.17 1.47 −0.69 0.03 1.42 −3.55 3.46
Note: All parameters are within the reference range.
Abbreviations: BMI, body mass index; n, number of patients; SDS, SD score.
FIGURE 1 Severity of dystonia and development of body
weight (SDS). Development of body weight was normal in
asymptomatic patients and those with mild or moderate dystonia,
but impaired in those with severe dystonia (F[3,238] = 20.42;
P < .001). SDS, SD score
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3.4.3 | Gender
Increased head circumference was more pronounced in
female (mean SDS 0.56) than in male patients (mean SDS
−0.2; P = .067; Supporting Information Figure S2), which
was confirmed in a linear model including biochemical
subtype and gender (P = .049). In contrast, SDS for body
weight, body length and BMI did not differ.
3.4.4 | Migration background
Migration background had no impact on anthropometric
development.
3.5 | Effects of interventional
parameters
3.5.1 | Maintenance treatment
Treatment quality has the strongest impact on neurologic
outcome in a screened population, a notion supported by
93% of patients, who adhered to MT and ET, having
remained asymptomatic.13 In contrast to the negative
effect on neurologic outcome, however, non-adherence to
MT had no significant direct impact on anthropometric
development. Mean SDS for weight was 0.01 for patients
with AMT and −0.44 for patients without (P = .303).
Results for length (mean SDS −0.30 [AMT] vs −0.41 [no
AMT]; P = .738), BMI (mean SDS 0.24 [AMT] vs −0.24
[no AMT]; P = .243) and head circumference (0.25
[AMT] vs −0.04 [no AMT]; P = .583) did not differ
(Supporting Information Figure S3).
3.5.2 | Emergency treatment
Delayed ET results in strongly increased risk of acute
onset and mainly severe dystonic MD.13 Accordingly,
non-adherence to ET had a significantly negative
impact on body length (mean SDS −1.34 [no AET] vs
−0.19 [AET]; P = .018) and also tended to impair body
weight (mean SDS −1.07 [no AET] vs .04 [AET];
P = .082; Figure 3). Both effects were confirmed and
significant in a linear model with P = .016 (body
length) and P = .023 (body weight). Of note, since del-
ayed ET and severe dystonia were associated, effects
may also reflect impact of MD. AET did not affect BMI
and head circumference.
3.5.3 | Supervision by a metabolic centre
Patients not followed by a metabolic centre showed a
trend towards impaired body length (mean SDS −0.83 vs
−0.26; P = .073), which, however, was not confirmed in a
linear model including AET and supervision by a meta-
bolic centre (P = .333). Body weight, BMI and head cir-
cumference did not differ between these patients.
4 | DISCUSSION
The major findings of this study investigating the long-
term anthropometric development of 79 individuals with
GA1 identified by NBS in Germany between 1999 and
2016 are (a) MT according to guideline recommendations
allows normal anthropometric development and prevents
malnutrition up to adolescence in all but severely
affected patients; (b) adherence to ET is crucial for both
neurologic and anthropometric outcome; (c) severity of
dystonic MD has a strong impact on anthropometric
long-term development; and (d) head circumference is
more pronounced in patients with HE phenotype as well
as in female patients.
4.1 | Dietary management according to
guideline recommendations is safe
Until now, effects and safety of recommended dietary
treatment for GA1 have not been evaluated for adoles-
cent or adult patients, but was shown to be safe up to
FIGURE 2 Biochemical subtype and head circumference
(SDS) at last visit. Head circumference in HE patients (mean SDS
0.44) was increased compared to LE patients (mean SDS −0.68;
P = .016). HE, high excreter; LE, low excreter; SDS, SD score
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the age 6 years in treated patients.22,28 According to the
guideline, lysine intake should continue to be limited
after age 6 years due to the uncertain neurologic and
extra-neurologic long-term disease course including
kidney dysfunction in adolescent patients,23 reports on
progredient extrastriatal abnormalities such as white
matter disease, subependymal nodules or CNS
tumours9,29 and progredient clinical course in lately
diagnosed patients.30 However, the guideline recom-
mends a relaxation of dietary treatment after the age of
6 years changing from the low lysine to a protein-
controlled diet since striatal injury has not been demon-
strated after the age of 6 years,1 and current therapeutic
concepts do not stop or slow extrastriatal MRI abnor-
malities that are regularly found especially in patients
younger age 6 years with HE phenotype treated with
low lysine diet.31 Since safety and efficacy of protein-
controlled diet has not yet been studied in detail for this
age group, the risk of malnutrition with potentially neg-
ative impact on long-term anthropometric development
and other clinical outcomes has remained unknown.
Here, we show that recommended MT is safe until
adolescence and early adulthood ensuring normal
growth and preventing malnutrition in the vast major-
ity of patients. None of the patients developed new
major or minor motor symptoms after the age of
6 years demonstrating that protein-controlled diet after
the age 6 years is effective and promotes favourable
neurologic outcome, however, long-term impact of die-
tary treatment, especially on unclear outcome domains
such as extrastriatal9 or renal23,24 abnormalities
remains to be elucidated. Noteworthy, deviations of
MT from current recommendations being associated
with an increased risk to develop insidious onset MD13
did not directly impair anthropometric outcome. How-
ever, adherence to MT is crucial and neurologic out-
come was superior in patients showing full adherence
to MT recommendations.13
4.2 | ET is crucial: Severe dystonia is the
major risk factor for poor anthropometric
outcome
Adherence to recommended ET is essential to prevent acute
onset MD, which is often severe and results in reduced life
expectancy and increased mortality.1,2,13 Consistent with the
findings of a previous study focussing on short-term out-
come, patients with severe MD are at risk for strongly
impaired anthropometric long-term development.22 Our
study shows that this impairment progresses continuously
with age until adolescence and adulthood highlighting the
need for intensive supervision and adaption of protein, calo-
ries and micronutrient intakes, individualisation of treat-
ment plans or (intermittant) tube feeding if necessary.
Affected patients may have increased energy demand
despite immobility or even reduced energy demand32 and
should therefore be monitored carefully. As severely affected
patients often also suffer from orofacial dyskinesia,33 special
interdisciplinary care and nutritional concepts are necessary
to assure adequate nutrition in these patients.
4.3 | Impact of neurotoxins: HE
phenotype as a risk factor for
macrocephaly
The neurotoxic metabolites glutaryl-CoA, GA and 3OHGA
are thought to play an important role in the pathophysiology
of GA1. GA interferes with anaplerotic transport processes
between astrocytes and neurons,34 and 3OHGA is
thought to interfere with glutamatergic and GABAergic
neurotransmission,35 and induces brain energy impair-
ment and increased generation of reactive oxygen spe-
cies.7,36-38 Besides, cerebrovascular changes resulting in
altered autoregulation and cerebral venous hypertension
subsequently increase the risk for haemorrhages.39,40
Concentrations of neurotoxic metabolites can be
FIGURE 3 Effect of
adherence to emergency
treatment and body length (A;
SDS), body weight (B; SDS) at
last visit. Delayed or no AET
had a negative impact on body
length (A; mean SDS −1.34
[no AET] vs −0.19 [AET];
P = .016) and body weight (B;
mean SDS −1.07 [no AET] vs
0.04 [AET]; P = .023).
AET, adherence to emergency
treatment; SDS, SD score
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modulated by the amount of lysine intake: While high oral
lysine intake leads to increased cerebral concentrations of
GA and subsequently to irreversible neurologic damage in
Gcdh-deficient mice,41 a low lysine diet reduces cerebral
concentrations of neurotoxic metabolites significantly.42,43
In spite of different peripheral concentrations of neuro-
toxins in urine or blood, post-mortem studies showed a
massive intracerebral accumulation of GA and 3OHGA in
both, HE and LE patients.44 This was explained by intrace-
rebral de novo synthesis and entrapment of neurotoxic
metabolites due to a limited permeability of the blood-brain
barrier for dicarboxylic acids.5 Consistent with this, HE and
LE patients are thought to share the same clinical course,
that is, the same risk of developing acute EC and dystonic
MD,1,4 which also was confirmed in our study cohort
before.13 In addition to a similar neurological motor out-
come, HE and LE patients also show the same risk for
decline in kidney function over time.13 However, in vivo
brain metabolic profiles are different in HE and LE patients
revealing normal concentrations of GA in LE patients, but
significantly increased concentrations in HE patients.9
Moreover, extrastriatal MRI abnormalities such as
frontotemporal hypoplasia, widening of sylvian fissures or
white matter abnormalities are more frequent in HE than
in LE patients.9,30 Of note, all three reported individuals
developing CNS tumours were HE patients.29 However,
clinical consequences of these observations remain unclear.
This is the first study revealing a clinical impact of biochem-
ical subtypes in GA1 with HE patients showing a signifi-
cantly larger head circumference than LE patients. This
also might explain why the vast majority of patients suffer-
ing from subdural haemorrhage are HE patients while only
one case of a LE patient was reported.39,45,46 Nevertheless,
impact of biochemical subtype on clinical outcome and
long-term development remains to be elucidated.
In line with this, the interesting finding of larger head
circumference in female compared to male patients that we
observed should be investigated in further studies. In
healthy children up to the age of 7 years, similar develop-
ment of head circumference for boys and girls has been
reported.47 Until now, no differences regarding concentra-
tions of metabolites, proportions of biochemical subtypes or
clinical outcome between female and male GA1 patients
have been published, nor has it been demonstrated in this
study. This finding should be further investigated by future
GA1 studies focussing on biochemical and clinical long-term
disease course as well as neuroradiologic and MRI patterns.
4.4 | Study limitations
First, a multi-centre study assessing anthropometric data
in children followed by numerous different metabolic
centres or hospitals has to admit possible measurement
inaccuracies. Second, there is no recently published refer-
ence population available for patients with migration
background but the reference population published by
Cole et al was assessed as an adequate reference since a
relevant proportion in this study had a migration back-
ground.26 Third, as a detailed analysis of laboratory data
was not possible due to insufficient data quality, malnu-
trition could only be evaluated clinically, and not
biochemically.
In summary, this study shows that treatment
according to guideline recommendations in GA1 is safe
and ensures normal anthropometric development up to
adolescence with gender- and excreter-specific variations,
while delayed ET with concomitantly severe MD is the
major cause of poor anthropometric outcome in screened
individuals with GA1.
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